In October 2023, Sanofi inked a potential $1.5 billion partnership with Teva Pharmaceuticals to develop TEV’574, an investigational anti-TL1A agent being studied for ulcerative colitis and Crohn’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback